Skip to main content
. 2021 Feb 1;131(3):e140315. doi: 10.1172/JCI140315

Figure 5. Targeting the VLA4/VCAM1 pathway reduces permeability and lessens ascites in vivo.

Figure 5

(A) Schematic of experimental design for the permeability assay in vivo. Clod, clodronate liposomes; treated cell, RAW264.7 cells with VLA4 knockdown or overexpression. (B and C) Evaluation of peritoneal permeability 48 hours after injection of VLA4 knockdown (B) or overexpression (C) cells in the peritoneum of mice (n = 5). (D) Evaluation of peritoneal permeability 48 hours after injection of PS/2-treated cells in the peritoneum of mice treated with liposomes (n = 8 for PBS lipo group; n = 9 for PBS lipo+PS/2 group; n = 7 for Clod Lipo; n = 9 for Clod lipo+PS/2). (E) Schematic of experimental design for treating ascites in OC animal. (F) Representative photographs of adult mice with OC sacrificed 10 days after PS/2 or IgG2b treatment and the ascites each mouse produced. (G) Ascites volume from PS/2- or control antibody–treated OC mice 12 days after HM-1 inoculation (n = 10). (H) ROS expression of ECs in tissue after treatment with PS/2 in mice with OC (n = 5). (I–M) Expression of RAC1 (I–J) and p-PYK2 and p–VE-cad (K–M) in murine OC tumors detected by immunofluorescence (n = 6). Scale bars: 50 μm. Results represent 3 independent experiments. Results are shown as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001, ****P < 0.0001, 1-way ANOVA (B and D) and Student’s t test (C, G, H, J, L, and M).